 | • レポートコード：GIR-203B16087 • 出版社/出版日：GlobalInfoResearch / 2021年12月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、85ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| PARP阻害剤ベース抗がん剤市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界のPARP阻害剤ベース抗がん剤の市場規模は2020年のxxx米ドルから2021年にはxxx米ドルと推定され、2020年から2021年の間にxxx％の変化があります。世界のPARP阻害剤ベース抗がん剤の市場規模は次の5年間でxxx％のCAGRで成長すると予想されます。 PARP阻害剤ベース抗がん剤市場は種類と用途によって区分されます。2016年～2026年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・リンパルザ、ゼジュラ、ルブラカ、タルゼンナ 用途別セグメントは次のように区分されます。 ・卵巣がん、乳がん、その他 世界のPARP阻害剤ベース抗がん剤市場の主要な市場プレーヤーは以下のとおりです。 ・AstraZeneca、Merck & Co、GSK、Clovis Oncology、Pfizer、Zai Lab 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計14章あります。 ・第1章では、PARP阻害剤ベース抗がん剤製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要なPARP阻害剤ベース抗がん剤メーカーの企業概要、2019年～2021年までのPARP阻害剤ベース抗がん剤の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要なPARP阻害剤ベース抗がん剤メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2016年～2026年までの地域別PARP阻害剤ベース抗がん剤の販売量、売上、成長性を示しています。 ・第5、6章では、2016年～2026年までのPARP阻害剤ベース抗がん剤の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2016年～2021年までの世界の主要国での販売量、売上、市場シェア、並びに2021年～2026年までの主要地域でのPARP阻害剤ベース抗がん剤市場予測を収録しています。 ・第12、13、14章では、PARP阻害剤ベース抗がん剤の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 ・メーカー情報（企業概要、製品概要、販売量、価格、売上）：AstraZeneca、Merck & Co、GSK、Clovis Oncology、Pfizer、Zai Lab ・メーカー別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：リンパルザ、ゼジュラ、ルブラカ、タルゼンナ ・用途別分析2016年-2026年：卵巣がん、乳がん、その他 ・PARP阻害剤ベース抗がん剤の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・PARP阻害剤ベース抗がん剤のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・PARP阻害剤ベース抗がん剤のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・PARP阻害剤ベース抗がん剤の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・PARP阻害剤ベース抗がん剤の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Cancer Drug based on PARP Inhibitor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Cancer Drug based on PARP Inhibitor size is estimated to be million in 2021 from USD million in 2020, with a change of % between 2020 and 2021. The global Cancer Drug based on PARP Inhibitor market size is expected to grow at a CAGR of % for the next five years.
Market segmentation
Cancer Drug based on PARP Inhibitor market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Lynparza
Zejula
Rubraca
Talzenna
Market segment by Application can be divided into
Ovarian Cancer
Breast Cancer
Other
The key market players for global Cancer Drug based on PARP Inhibitor market are listed below:
AstraZeneca
Merck & Co
GSK
Clovis Oncology
Pfizer
Zai Lab
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Cancer Drug based on PARP Inhibitor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Cancer Drug based on PARP Inhibitor, with price, sales, revenue and global market share of Cancer Drug based on PARP Inhibitor from 2019 to 2021.
Chapter 3, the Cancer Drug based on PARP Inhibitor competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Cancer Drug based on PARP Inhibitor breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Cancer Drug based on PARP Inhibitor market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Cancer Drug based on PARP Inhibitor sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Cancer Drug based on PARP Inhibitor Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Cancer Drug based on PARP Inhibitor Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Lynparza
1.2.3 Zejula
1.2.4 Rubraca
1.2.5 Talzenna
1.3 Market Analysis by Application
1.3.1 Overview: Global Cancer Drug based on PARP Inhibitor Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Ovarian Cancer
1.3.3 Breast Cancer
1.3.4 Other
1.4 Global Cancer Drug based on PARP Inhibitor Market Size & Forecast
1.4.1 Global Cancer Drug based on PARP Inhibitor Sales in Value (2016-2026))
1.4.2 Global Cancer Drug based on PARP Inhibitor Sales in Volume (2016-2026)
1.4.3 Global Cancer Drug based on PARP Inhibitor Price by Type (2016-2026) & (US$/Unit)
1.5 Global Cancer Drug based on PARP Inhibitor Production Capacity Analysis
1.5.1 Global Cancer Drug based on PARP Inhibitor Total Production Capacity (2016-2026)
1.5.2 Global Cancer Drug based on PARP Inhibitor Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Cancer Drug based on PARP Inhibitor Market Drivers
1.6.2 Cancer Drug based on PARP Inhibitor Market Restraints
1.6.3 Cancer Drug based on PARP Inhibitor Trends Analysis
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Cancer Drug based on PARP Inhibitor Product and Services
2.1.4 AstraZeneca Cancer Drug based on PARP Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Merck & Co
2.2.1 Merck & Co Details
2.2.2 Merck & Co Major Business
2.2.3 Merck & Co Cancer Drug based on PARP Inhibitor Product and Services
2.2.4 Merck & Co Cancer Drug based on PARP Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 GSK
2.3.1 GSK Details
2.3.2 GSK Major Business
2.3.3 GSK Cancer Drug based on PARP Inhibitor Product and Services
2.3.4 GSK Cancer Drug based on PARP Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Clovis Oncology
2.4.1 Clovis Oncology Details
2.4.2 Clovis Oncology Major Business
2.4.3 Clovis Oncology Cancer Drug based on PARP Inhibitor Product and Services
2.4.4 Clovis Oncology Cancer Drug based on PARP Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer Cancer Drug based on PARP Inhibitor Product and Services
2.5.4 Pfizer Cancer Drug based on PARP Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Zai Lab
2.6.1 Zai Lab Details
2.6.2 Zai Lab Major Business
2.6.3 Zai Lab Cancer Drug based on PARP Inhibitor Product and Services
2.6.4 Zai Lab Cancer Drug based on PARP Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Cancer Drug based on PARP Inhibitor Sales by Manufacturer
3.1 Global Cancer Drug based on PARP Inhibitor Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Cancer Drug based on PARP Inhibitor Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Cancer Drug based on PARP Inhibitor
3.4 Market Concentration Rate
3.4.1 Top 3 Cancer Drug based on PARP Inhibitor Manufacturer Market Share
3.4.2 Top 6 Cancer Drug based on PARP Inhibitor Manufacturer Market Share
3.5 Global Cancer Drug based on PARP Inhibitor Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Cancer Drug based on PARP Inhibitor Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Cancer Drug based on PARP Inhibitor Market Size by Region
4.1.1 Global Cancer Drug based on PARP Inhibitor Sales in Volume by Region (2016-2026)
4.1.2 Global Cancer Drug based on PARP Inhibitor Revenue by Region (2016-2026)
4.2 North America Cancer Drug based on PARP Inhibitor Revenue (2016-2026)
4.3 Europe Cancer Drug based on PARP Inhibitor Revenue (2016-2026)
4.4 Asia-Pacific Cancer Drug based on PARP Inhibitor Revenue (2016-2026)
4.5 South America Cancer Drug based on PARP Inhibitor Revenue (2016-2026)
4.6 Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Cancer Drug based on PARP Inhibitor Sales in Volume by Type (2016-2026)
5.2 Global Cancer Drug based on PARP Inhibitor Revenue by Type (2016-2026)
5.3 Global Cancer Drug based on PARP Inhibitor Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Cancer Drug based on PARP Inhibitor Sales in Volume by Application (2016-2026)
6.2 Global Cancer Drug based on PARP Inhibitor Revenue by Application (2016-2026)
6.3 Global Cancer Drug based on PARP Inhibitor Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Cancer Drug based on PARP Inhibitor Sales by Type (2016-2026)
7.2 North America Cancer Drug based on PARP Inhibitor Sales by Application (2016-2026)
7.3 North America Cancer Drug based on PARP Inhibitor Market Size by Country
7.3.1 North America Cancer Drug based on PARP Inhibitor Sales in Volume by Country (2016-2026)
7.3.2 North America Cancer Drug based on PARP Inhibitor Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Cancer Drug based on PARP Inhibitor Sales by Type (2016-2026)
8.2 Europe Cancer Drug based on PARP Inhibitor Sales by Application (2016-2026)
8.3 Europe Cancer Drug based on PARP Inhibitor Market Size by Country
8.3.1 Europe Cancer Drug based on PARP Inhibitor Sales in Volume by Country (2016-2026)
8.3.2 Europe Cancer Drug based on PARP Inhibitor Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Cancer Drug based on PARP Inhibitor Sales by Type (2016-2026)
9.2 Asia-Pacific Cancer Drug based on PARP Inhibitor Sales by Application (2016-2026)
9.3 Asia-Pacific Cancer Drug based on PARP Inhibitor Market Size by Region
9.3.1 Asia-Pacific Cancer Drug based on PARP Inhibitor Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Cancer Drug based on PARP Inhibitor Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Cancer Drug based on PARP Inhibitor Sales by Type (2016-2026)
10.2 South America Cancer Drug based on PARP Inhibitor Sales by Application (2016-2026)
10.3 South America Cancer Drug based on PARP Inhibitor Market Size by Country
10.3.1 South America Cancer Drug based on PARP Inhibitor Sales in Volume by Country (2016-2026)
10.3.2 South America Cancer Drug based on PARP Inhibitor Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Cancer Drug based on PARP Inhibitor Sales by Type (2016-2026)
11.2 Middle East & Africa Cancer Drug based on PARP Inhibitor Sales by Application (2016-2026)
11.3 Middle East & Africa Cancer Drug based on PARP Inhibitor Market Size by Country
11.3.1 Middle East & Africa Cancer Drug based on PARP Inhibitor Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Cancer Drug based on PARP Inhibitor Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Cancer Drug based on PARP Inhibitor Typical Distributors
12.3 Cancer Drug based on PARP Inhibitor Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Cancer Drug based on PARP Inhibitor Revenue by Type, (USD Million), 2021-2026
Table 2. Global Cancer Drug based on PARP Inhibitor Revenue by Application, (USD Million), 2021-2026
Table 3. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 4. AstraZeneca Major Business
Table 5. AstraZeneca Cancer Drug based on PARP Inhibitor Product and Services
Table 6. AstraZeneca Cancer Drug based on PARP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Merck & Co Basic Information, Manufacturing Base and Competitors
Table 8. Merck & Co Major Business
Table 9. Merck & Co Cancer Drug based on PARP Inhibitor Product and Services
Table 10. Merck & Co Cancer Drug based on PARP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. GSK Basic Information, Manufacturing Base and Competitors
Table 12. GSK Major Business
Table 13. GSK Cancer Drug based on PARP Inhibitor Product and Services
Table 14. GSK Cancer Drug based on PARP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Clovis Oncology Basic Information, Manufacturing Base and Competitors
Table 16. Clovis Oncology Major Business
Table 17. Clovis Oncology Cancer Drug based on PARP Inhibitor Product and Services
Table 18. Clovis Oncology Cancer Drug based on PARP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Pfizer Basic Information, Manufacturing Base and Competitors
Table 20. Pfizer Major Business
Table 21. Pfizer Cancer Drug based on PARP Inhibitor Product and Services
Table 22. Pfizer Cancer Drug based on PARP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Zai Lab Basic Information, Manufacturing Base and Competitors
Table 24. Zai Lab Major Business
Table 25. Zai Lab Cancer Drug based on PARP Inhibitor Product and Services
Table 26. Zai Lab Cancer Drug based on PARP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Global Cancer Drug based on PARP Inhibitor Sales by Manufacturer (2019-2021e) & (K Units)
Table 28. Global Cancer Drug based on PARP Inhibitor Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 29. Market Position of Manufacturers in Cancer Drug based on PARP Inhibitor, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 30. Global Cancer Drug based on PARP Inhibitor Production Capacity by Company, (K Units): 2020 VS 2021
Table 31. Head Office and Cancer Drug based on PARP Inhibitor Production Site of Key Manufacturer
Table 32. Cancer Drug based on PARP Inhibitor New Entrant and Capacity Expansion Plans
Table 33. Cancer Drug based on PARP Inhibitor Mergers & Acquisitions in the Past Five Years
Table 34. Global Cancer Drug based on PARP Inhibitor Sales by Region (2016-2021e) & (K Units)
Table 35. Global Cancer Drug based on PARP Inhibitor Sales by Region (2021-2026) & (K Units)
Table 36. Global Cancer Drug based on PARP Inhibitor Revenue by Region (2016-2021e) & (USD Million)
Table 37. Global Cancer Drug based on PARP Inhibitor Revenue by Region (2021-2026) & (USD Million)
Table 38. Global Cancer Drug based on PARP Inhibitor Sales by Type (2016-2021e) & (K Units)
Table 39. Global Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units)
Table 40. Global Cancer Drug based on PARP Inhibitor Revenue by Type (2016-2021e) & (USD Million)
Table 41. Global Cancer Drug based on PARP Inhibitor Revenue by Type (2021-2026) & (USD Million)
Table 42. Global Cancer Drug based on PARP Inhibitor Price by Type (2016-2021e) & (US$/Unit)
Table 43. Global Cancer Drug based on PARP Inhibitor Price by Type (2021-2026) & (US$/Unit)
Table 44. Global Cancer Drug based on PARP Inhibitor Sales by Application (2016-2021e) & (K Units)
Table 45. Global Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units)
Table 46. Global Cancer Drug based on PARP Inhibitor Revenue by Application (2016-2021e) & (USD Million)
Table 47. Global Cancer Drug based on PARP Inhibitor Revenue by Application (2021-2026) & (USD Million)
Table 48. Global Cancer Drug based on PARP Inhibitor Price by Application (2016-2021e) & (US$/Unit)
Table 49. Global Cancer Drug based on PARP Inhibitor Price by Application (2021-2026) & (US$/Unit)
Table 50. North America Cancer Drug based on PARP Inhibitor Sales by Country (2016-2021e) & (K Units)
Table 51. North America Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026) & (K Units)
Table 52. North America Cancer Drug based on PARP Inhibitor Revenue by Country (2016-2021e) & (USD Million)
Table 53. North America Cancer Drug based on PARP Inhibitor Revenue by Country (2021-2026) & (USD Million)
Table 54. North America Cancer Drug based on PARP Inhibitor Sales by Type (2016-2021e) & (K Units)
Table 55. North America Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units)
Table 56. North America Cancer Drug based on PARP Inhibitor Sales by Application (2016-2021e) & (K Units)
Table 57. North America Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units)
Table 58. Europe Cancer Drug based on PARP Inhibitor Sales by Country (2016-2021e) & (K Units)
Table 59. Europe Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026) & (K Units)
Table 60. Europe Cancer Drug based on PARP Inhibitor Revenue by Country (2016-2021e) & (USD Million)
Table 61. Europe Cancer Drug based on PARP Inhibitor Revenue by Country (2021-2026) & (USD Million)
Table 62. Europe Cancer Drug based on PARP Inhibitor Sales by Type (2016-2021e) & (K Units)
Table 63. Europe Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units)
Table 64. Europe Cancer Drug based on PARP Inhibitor Sales by Application (2016-2021e) & (K Units)
Table 65. Europe Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units)
Table 66. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales by Region (2016-2021e) & (K Units)
Table 67. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales by Region (2021-2026) & (K Units)
Table 68. Asia-Pacific Cancer Drug based on PARP Inhibitor Revenue by Region (2016-2021e) & (USD Million)
Table 69. Asia-Pacific Cancer Drug based on PARP Inhibitor Revenue by Region (2021-2026) & (USD Million)
Table 70. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales by Type (2016-2021e) & (K Units)
Table 71. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units)
Table 72. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales by Application (2016-2021e) & (K Units)
Table 73. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units)
Table 74. South America Cancer Drug based on PARP Inhibitor Sales by Country (2016-2021e) & (K Units)
Table 75. South America Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026) & (K Units)
Table 76. South America Cancer Drug based on PARP Inhibitor Revenue by Country (2016-2021e) & (USD Million)
Table 77. South America Cancer Drug based on PARP Inhibitor Revenue by Country (2021-2026) & (USD Million)
Table 78. South America Cancer Drug based on PARP Inhibitor Sales by Type (2016-2021e) & (K Units)
Table 79. South America Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units)
Table 80. South America Cancer Drug based on PARP Inhibitor Sales by Application (2016-2021e) & (K Units)
Table 81. South America Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units)
Table 82. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales by Country (2016-2021e) & (K Units)
Table 83. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026) & (K Units)
Table 84. Middle East & Africa Cancer Drug based on PARP Inhibitor Revenue by Country (2016-2021e) & (USD Million)
Table 85. Middle East & Africa Cancer Drug based on PARP Inhibitor Revenue by Country (2021-2026) & (USD Million)
Table 86. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales by Type (2016-2021e) & (K Units)
Table 87. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units)
Table 88. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales by Application (2016-2021e) & (K Units)
Table 89. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units)
Table 90. Direct Channel Pros & Cons
Table 91. Indirect Channel Pros & Cons
Table 92. Cancer Drug based on PARP Inhibitor Typical Distributors
Table 93. Cancer Drug based on PARP Inhibitor Typical Customers
List of Figures
Figure 1. Cancer Drug based on PARP Inhibitor Picture
Figure 2. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type in 2020
Figure 3. Lynparza
Figure 4. Zejula
Figure 5. Rubraca
Figure 6. Talzenna
Figure 7. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application in 2020
Figure 8. Ovarian Cancer
Figure 9. Breast Cancer
Figure 10. Other
Figure 11. Global Cancer Drug based on PARP Inhibitor Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 12. Global Cancer Drug based on PARP Inhibitor Market Size and Forecast (2016-2026) & (USD Million)
Figure 13. Global Cancer Drug based on PARP Inhibitor Sales (2016-2026) & (K Units)
Figure 14. Global Cancer Drug based on PARP Inhibitor Price by Type (2016-2026) & (US$/Unit)
Figure 15. Global Cancer Drug based on PARP Inhibitor Production Capacity (2016-2026) & (K Units)
Figure 16. Global Cancer Drug based on PARP Inhibitor Production Capacity by Geographic Region: 2020 VS 2021
Figure 17. Cancer Drug based on PARP Inhibitor Market Drivers
Figure 18. Cancer Drug based on PARP Inhibitor Market Restraints
Figure 19. Cancer Drug based on PARP Inhibitor Market Trends
Figure 20. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Manufacturer in 2020
Figure 21. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Manufacturer in 2020
Figure 22. Cancer Drug based on PARP Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 23. Top 3 Cancer Drug based on PARP Inhibitor Manufacturer (Revenue) Market Share in 2020
Figure 24. Top 6 Cancer Drug based on PARP Inhibitor Manufacturer (Revenue) Market Share in 2020
Figure 25. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2016-2026)
Figure 26. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2016-2026)
Figure 27. North America Cancer Drug based on PARP Inhibitor Revenue (2016-2026) & (USD Million)
Figure 28. Europe Cancer Drug based on PARP Inhibitor Revenue (2016-2026) & (USD Million)
Figure 29. Asia-Pacific Cancer Drug based on PARP Inhibitor Revenue (2016-2026) & (USD Million)
Figure 30. South America Cancer Drug based on PARP Inhibitor Revenue (2016-2026) & (USD Million)
Figure 31. Middle East & Africa Cancer Drug based on PARP Inhibitor Revenue (2016-2026) & (USD Million)
Figure 32. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2016-2026)
Figure 33. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2016-2026)
Figure 34. Global Cancer Drug based on PARP Inhibitor Price by Type (2016-2026) & (US$/Unit)
Figure 35. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2016-2026)
Figure 36. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2016-2026)
Figure 37. Global Cancer Drug based on PARP Inhibitor Price by Application (2016-2026) & (US$/Unit)
Figure 38. North America Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2016-2026)
Figure 39. North America Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2016-2026)
Figure 40. North America Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2016-2026)
Figure 41. North America Cancer Drug based on PARP Inhibitor Revenue Market Share by Country (2016-2026)
Figure 42. United States Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Canada Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Mexico Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Europe Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2016-2026)
Figure 46. Europe Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2016-2026)
Figure 47. Europe Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2016-2026)
Figure 48. Europe Cancer Drug based on PARP Inhibitor Revenue Market Share by Country (2016-2026)
Figure 49. Germany Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. France Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. United Kingdom Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Russia Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Italy Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2016-2026)
Figure 55. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2016-2026)
Figure 56. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2016-2026)
Figure 57. Asia-Pacific Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2016-2026)
Figure 58. China Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Japan Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Korea Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. India Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Southeast Asia Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Australia Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South America Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2016-2026)
Figure 65. South America Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2016-2026)
Figure 66. South America Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2016-2026)
Figure 67. South America Cancer Drug based on PARP Inhibitor Revenue Market Share by Country (2016-2026)
Figure 68. Brazil Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Argentina Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2016-2026)
Figure 71. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2016-2026)
Figure 72. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2016-2026)
Figure 73. Middle East & Africa Cancer Drug based on PARP Inhibitor Revenue Market Share by Country (2016-2026)
Figure 74. Turkey Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Egypt Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Saudi Arabia Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. South Africa Cancer Drug based on PARP Inhibitor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source
腫瘍/がん治療薬（抗がん剤） のグローバル市場 2021年：企業別、地域別、種類・用途別 The Oncology & Cancer Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…- 細菌性膣炎用処方薬のグローバル市場 2021年：企業別、地域別、種類・用途別 The Bacterial Vaginosis Rx Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade reg…
- HDIベースポリイソシアネートのグローバル市場 2021年：企業別、地域別、種類・用途別 The HDI Based Polyisocyanate market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regula…
- リグニンベースグラフェンのグローバル市場 2021年：企業別、地域別、種類・用途別 The Lignin-Based Graphene market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulatio…
- セルロースベース膜のグローバル市場 2021年：企業別、地域別、種類・用途別 The Cellulose Based Membranes market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regul…